Daily Rounds

🧬 Epigenetic Age Reversed 3+ Years — A clinical trial of 5-nucleotide supplementation reversed DNA methylation age by over three years in adults aged 60 to 70. 🧠 Protein FTL1 Linked to Memory Decline — A newly identified protein weakens neuronal connections in aging brains, pointing to a potential new therapeutic target for cognitive decline. 🤖 AI Drug Industry Enters Clinical Era — With 173+ AI-designed drugs in human trials and Eli Lilly's $2.75B Insilico deal, AI is now a defining force in pharmaceutical development. 🦠 Gut Bacteria Directly Control Human Immune Cells — Helmholtz Munich scientists discover common gut microbes inject proteins into human cells to shape immune behavior, a mechanism linked to inflammatory disease. 😴 Sleep Consistency Matters More Than Duration — New research shows that regularity of sleep timing predicts physical and mental wellbeing better than total sleep hours in older adults.

🔬 Aging Reframed as Coordination Loss: Scientists at the 2026 World Longevity Congress argue that preserving biological coordination across systems, not fixing individual defects, is the new paradigm for healthy aging. 🧠 Exercise Plus Sleep Cuts Dementia Risk: A new meta-analysis confirms that regular physical activity combined with 7 to 8 hours of nightly sleep significantly reduces dementia risk later in life. 🤖 AI Drug Pipeline Hits 173 Clinical Programs: AI-discovered drug programs are advancing rapidly, with over 173 now in clinical trials and up to 20 pivotal trials expected to launch in 2026. 🦠 Gut Bacteria Directly Reshape Human Immune Responses: Common gut microbes inject proteins into human cells, actively shaping immune behavior in ways potentially central to inflammatory disease and future therapies. 😴 Circadian Misalignment Under Study as Liver Cancer Driver: New Fred Hutch research will investigate whether disrupted internal body clocks increase risk of hepatocellular carcinoma, adding to the growing evidence linking circadian health to cancer risk.

🧬 Aging Reframed as Coordination Failure: Scientists at the World Longevity Congress are shifting from single-target anti-aging interventions toward restoring coordination across the body's biological systems. ❤️ Long COVID and the Heart: A 1.2-million-person Swedish study confirms long COVID significantly raises cardiovascular disease risk, including in younger non-hospitalized adults, with women facing more than double the risk. 🤖 AI Hits a Clinical Milestone: With 173 AI-discovered drugs now in clinical trials and Insilico's AI-designed pulmonary fibrosis drug showing Phase IIa efficacy, generative AI in medicine has arrived at clinical scale. 🦠 Fasting for Gut Health: Just five days per month of low-calorie plant-based eating reduced gut inflammation and achieved clinical response in nearly 70% of Crohn's disease patients in a Nature Medicine randomized trial. 😴 Circadian Health and Cancer: New ACS-funded research at Fred Hutch will investigate whether night-shift-driven solar jet lag is a driver of liver cancer, reinforcing circadian alignment as a cancer prevention frontier.

🔬 Aging Redefined as Systems Failure: Researchers in Berlin are shifting the aging conversation toward preserving biological coordination across systems, not fixing a single defect. 🤖 AI Drug Discovery Reaches Scale: Over 173 AI-discovered drug programs are now in clinical trials, and a new free platform targeting global diseases launched this week. 😴 Sleep as a Disease Predictor: Stanford's SleepFM AI model predicts 130+ conditions from one night of sleep data, positioning sleep as a critical longevity biomarker. 🦠 Gut Microbiome Controls Immunity Directly: Common gut microbes inject proteins into immune cells, and a single bacterial metabolite doubled lung cancer immunotherapy response in mice. ❤️ Long-Term Heart-Aging Study Begins: UTMB's decade-long Galveston Heart Study will track thousands of participants to uncover how cardiovascular and brain health intersect with aging.

🧬 - Epigenetic reprogramming enters human trials for the first time, with Life Biosciences' ER-100 receiving FDA clearance for a phase 1 study in optic nerve degeneration, marking the dawn of cellular rejuvenation medicine. 🫁 - An AI-designed molecule for idiopathic pulmonary fibrosis shows clinical promise in a phase 2a trial, proving that algorithmically discovered drugs can survive contact with human biology. 🦠 - Gut bacteria can inject proteins directly into human cells, a newly described mechanism now linked to Crohn's disease inflammation and poised to reshape microbiome therapeutics. 🧠 - Disrupted circadian rhythms are associated with 2.5 times the risk of dementia, reinforcing that sleep timing and biological clock integrity are modifiable targets for brain aging. 💊 - With more than 173 AI-discovered drug programs now in clinical trials and Eli Lilly committing $2.75 billion to AI drug development, the algorithmic era of medicine is no longer theoretical.

🧬 - Epigenetic reprogramming has entered human clinical trials for the first time, with Life Biosciences receiving FDA clearance to test partial reprogramming in retinal degeneration patients, a landmark moment for the entire longevity field. 🤖 - An AI-designed drug for pulmonary fibrosis showed a 160 mL treatment differential in forced vital capacity versus placebo in Phase IIa, suggesting the drug may stop or reverse disease progression rather than merely slowing it. 🦠 - Gut bacteria use molecular syringe-like structures to inject proteins directly into human cells, and this bacterial protein transfer is now linked to elevated Crohn's disease risk, redefining how the microbiome communicates with the immune system. ❤️ - A new cardiovascular drug class reduces heart attack and stroke risk in older adults by nearly 20 percent by simultaneously targeting cholesterol, inflammation, and blood sugar, pointing toward a potential revision of current standard-of-care protocols. ⏰ - Circadian biology is entering the clinic, with evidence that vaccine timing, sleep medication evaluation, and cardiovascular risk management all benefit from treating the biological clock as a measurable and modifiable variable rather than background noise.

🧬 Epigenetic reprogramming enters its first human trial as Life Biosciences begins treating retinal degeneration with ER-100, a cellular rejuvenation therapy that resets the biological clock without erasing cell identity. 💊 A gut bacteria compound doubles lung cancer immunotherapy response rates in preclinical models, pointing to the microbiome as a powerful and underutilized lever in oncology treatment protocols. 🤖 Over 173 AI-designed drug programs are now in human clinical trials, with 2026 marking the transition from AI-assisted research to AI-native drug discovery as a standard operating model. 🏋️ GLP-1 medications and exercise share a convergent molecular pathway through interleukin-6 signaling, meaning structured resistance and aerobic training is not just complementary to these medications but mechanistically synergistic. 😴 Consumer wearable sleep trackers have cleared the threshold for clinical validation, with the World Sleep Society formalizing recommendations that integrate these devices into clinical practice and disease management protocols.